Drug Type Small molecule drug |
Synonyms Nitendipine, Nitrenkipine, BAY-E-5009 + [4] |
Target |
Mechanism Cav2.1 inhibitors(calcium voltage-gated channel subunit alpha1 A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (01 Jan 1987), |
Regulation- |
Molecular FormulaC18H20N2O6 |
InChIKeyPVHUJELLJLJGLN-UHFFFAOYSA-N |
CAS Registry39562-70-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00629 | Nitrendipine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | CN | 01 Jan 1987 |
Not Applicable | 59 | Combined antihypertensive treatment with nitrendipine | ahtlplozvr(mpodvknddu) = cpstwtghvv axtjbfljou (jrrvoqfnll ) | - | 27 Aug 2023 | ||
Phase 4 | 1,405 | kcnyfkghiy(lvkaxfpylh) = vvfjwmrkze nsfvhmkqmo (dzhdujrshy ) | - | 01 Jun 2005 | |||
kcnyfkghiy(lvkaxfpylh) = gsysctgrtq nsfvhmkqmo (dzhdujrshy ) |